Business Daily Media

Men's Weekly

.

Novotech CRO strengthens South Korean Clinical Capabilities partnering with 2 Major Hospitals

  • Written by ACN Newswire
SYDNEY, Apr 18, 2019 - (ACN Newswire) - Novotech, the award-winning Asia-Pacific CRO with 23 years of experience in the region, has further strengthened its presence in South Korea with two major hospitals joining the Novotech partnership program - bringing more quality investigators, KOLs, and up to 4 million patients.

The 900 bed Ulsan University Hospital (UUH), and the Hepatology Division in Gastroenterology, Department of Internal Medicine at the 1,778 bed Seoul National University Hospital (SNUH), have joined the Novotech CRO partnership program, further strengthening Novotech's clinical service capabilities in South Korea.

South Korea is a fast-growing destination for clinical studies with quality infrastructure, world-class medical and hospital facilities, and supportive rapid start-up regulations. South Korea was Asia's most active country in clinical research after China last year, with over 400 sites opened by biopharma companies.

Novotech is well established in Asia with offices in 11 countries and more than 550 staff, while 19 leading hospitals and medical facilities across the region have now joined the Novotech CRO clinical partnership program.

Novotech CEO Dr John Moller said biotech clients were increasingly running Phase I studies in Australia, benefiting from the 41% R&D tax credit, then moving to Asia for subsequent trials. "Having the same company that understands the study as it transitions into Asia is always reassuring for clients. Novotech uses the latest Oracle and Medidata technology, so seamlessly connects with global clinical partners."

About Novotech - https://novotech-cro.com/welcome[1]Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials across the Asia Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management.

For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0[2]

Media Contact:[email protected]Susan Fitzpatrick-Napier, AU: +61 2 8218 2144USA: +1 415 951 3228, Asia: +65 3159 3427 [3]

Topic: Press release summarySectors: HealthCare[4] http://www.acnnewswire.com From the Asia Corporate News Network

Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

References

  1. ^ https://novotech-cro.com/welcome (novotech-cro.com)
  2. ^ www.novotech-cro.com/contact-us-0 (www.novotech-cro.com)
  3. ^ [email protected] (www.acnnewswire.com)
  4. ^ HealthCare (www.acnnewswire.com)

Read more http://www.acnnewswire.com/press-release/english/51234/

Refunds to Revenue: AI and loyalty perks help retailers in post-holiday hangover

Australian retailers are turning to artificial intelligence to simplify and automate returns and exchanges, while strengthening loyalty programs a...

Stop reading from the script: Why authenticity is the customer success secret weapon

I’ve been in customer service for years now. As my team has grown, the number one piece of advice I give is to be your...

From Check-in to Touchdown: How AI and smarter systems are transforming the travel industry

Richard Valente, VP of Customer Experience Strategy at TP in Australia, explores how IT-BPM outsourcing is revolutionising the travel sector throu...

Online Christmas shoppers fund climate and biodiversity projects via HealthPost's Click Sphere for Good initiative

Online shoppers with HealthPost’s Flora & Fauna have made 11,000 contributions towards climate and biodiversity projects when ordering parcel ...

US landmark settlement protects SMEs, highlighting flaws in the RBA's proposed blanket card surcharging ban for Australia

Aussie SMEs warn RBA not to ignore global trends, with the current sledgehammer approach threatening business viability and increasing inflation ...

Thryv Australia named Employer of Choice for third consecutive year at Australian Business Awards

Thryv® (NASDAQ: THRY), Australia’s provider of the leading small business marketing and sales software platform, has been awarded the Employer of ...